SOLICITATION NOTICE
70 -- Strand License, Technical Support, OR EQUAL
- Notice Date
- 9/8/2008
- Notice Type
- Combined Synopsis/Solicitation
- NAICS
- 541519
— Other Computer Related Services
- Contracting Office
- Department of Health and Human Services, Food and Drug Administration, Office of Acquisitions and Grants Services, 5630 Fishers Lane, Room 2129, Rockville, Maryland, 20857-0001
- ZIP Code
- 20857-0001
- Solicitation Number
- FDA-SOL-08-1043752
- Archive Date
- 9/26/2008
- Point of Contact
- Rafael Taylor,, Phone: 301-827-7169, Jody L. O'Kash,, Phone: 301-827-5094
- E-Mail Address
-
Rafael.Taylor@fda.hhs.gov, Jody.O'Kash@fda.hhs.gov
- Small Business Set-Aside
- Total Small Business
- Description
- (i) This is a combined/synopsis solicitation for commercial items prepared in accordance with the format in FAR 12.6, as supplemented with additional information included in this notice. (ii) This is solicitation number FDA-SOL-08-1043752 and this solicitation is being issued as a Request for Quote (RFQ). (iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2005-12. This is a total small business set-aside. (iv) The NAICS code is 541519. The size standard $25M. (v) The following is a list of essential salient characteristics required for the Genomics Reviewer desktop. DESCRIPTION OF REQUIREMENTS: STATEMENT OF WORK: Genomics Reviewer Desktop - Salient Characteristics - Functions - The Genomics Reviewer Desktop (henceforth “GRD”) should provide an integrated software application environment for reviewers to easily import, compare and analyze gene expression/genotyping analysis results from various gene expression analysis tools used internally at the FDA (henceforth “target applications”). - The GRD should support the ability to retrieve and store meta-information about the analysis parameters used (p-value cutoff, normalization algorithm, sample info etc.) along with the imported genelists. - The GRD should provide the ability to compare resulting genelists from such analyses and build a consensus genelist. The GRD should provide data visualization functions (Venn, Scatter, Profile, Histogram, Bar plots) on the imported genelists. - The GRD should provide the ability to integrate genelist results with their biological pathway interpretations from various pathway analysis tools used internally at FDA (‘target applications”). - The GRD should support an interactive pathway viewer. Nodes in the pathway should be cross-selectable on the saved genelists as well. - The GRD should provide the ability to build a consensus pathway from multiple pathways, and visualize it (perhaps highlighted against the original pathways). - The GRD should provide the ability to configure and automate data analysis workflows, by way of scripting and/or configuration files. - The GRD should provide the ability to automatically annotate genes based on common gene identifiers (such as Entrez Gene, Unigene id etc.) and probe identifiers (Affy, Agilent etc.). Annotation information should be updatable at regular frequency. - The GRD should provide the ability to retrieve adverse event data associated with specific genes from text mining public literature such as PubMed. Compatibility Requirements - - The GRD should be installable as a standalone application on a Windows XP workstation (assuming minimum 1.6Ghz processor, 1GB RAM). - The GRD should be able to exchange genelists and pathways (using compatible data formats such as tsv, csv, BioPax etc.) with target applications that the reviewer can run on his or her desktop. This includes but is not limited to ArrayTrack, JMP Genomics, Rosetta Resolver, HelixTree, Ingenuity Pathway Analysis, GeneGo etc. - The above functionality may depend on the availability of documented API (application programming interfaces) for importing/exporting data from the target applications. - An extensible plugin architecture is recommended to be used for interaction with the target applications, so new applications can be added without modifying the core software of the GRD. - The GRD should support the ability to manipulate large datasets of genes (say up to 100,000 genes) and large pathway graphs (say up to 1000 nodes). The following licenses are being purchased: 1 Each, Unlimited usage license. Unlimited electronic-User Guides will be made available to us by the Contractor. Support and maintenance during the first year after delivery shall be included as part of the maintenance and warranty. Contractor will provide technical support to us during normal business days. A primary and one secondary contact shall be available to address issues like bug fixes. In the event of an issue being reported, the contractor will take one business day to acknowledge the problem. Contractor may take up to 5 business days to identify the problem and give a work around to resolve the problem with a probable delivery date Contractor will be provided remote access support from the Government for installation and other troubleshooting events. Support for such events can be given via telephone, email and remote system access. Place of Performance. The place of performance shall be as indicated below: Office of Clinical Pharmacology, Office of Translational Science, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, 10903 New Hampshire Avenue, Building 51, Room 2148, Silver Spring, MD 20903-0002 Period of Performance. GRD creation shall be 3 months. FDA requires 2 weeks to complete the Acceptance Testing after the period of performance. GRD license will be perpetual. Biological Data and Pathways visualization software license shall be 1 year from installation. Performance Requirements Summary. The contractor will deliver the project based on the following matrix: 1 Meeting mutually agreed specifications, 2 Meeting timelines, 3 Meeting required quality standards, 4 Frequent communication and reporting, 5 Providing adequate levels of support, and 6 Provide an initial training on delivery. ALL (100%) functions shall perform as specified or in an equivalent way acceptable to the FDA. Evidence documenting the acceptance in form of an executed Accepted Test Plan will need to be submitted. (vi) Delivery of the product will be FOB destination. The contractor shall deliver the product to 5600 Fishers Lane, Rockville, MD 20857 no later than fourteen days after receipt of an award. Performance period will be should (vii) The provision at 52.212-1, Instructions to Offerors (APR 2008) -- Commercial, applies to this acquisition and is available at website: http://farsite.hill.af.mil/reghtml/regs/far2afmcfars/fardfars/far/12.htm#P257_45709. (viii) The provision at 52.212-1, Evaluation -- Commercial Items (Jan 1999) The Government will award a contract resulting from this solicitation to the responsible offeror whose offer conforming to the solicitation will offer the best value to the Government. This is a competitive best value source selection in which the Government will award a contract resulting from this solicitation to the responsible offeror whose offer conforming to the solicitation will be most advantageous to the Government, price, and other factors considered. Price is of less importance than technical capabilities and past performance combined. Award will not be automatically made on the basis of the highest technical merit. However price may become an important factor as the degree of equality between technical proposals becomes closer. To determine technical merit, each quotation will be evaluated against the technical evaluation factors. The following factors shall be used to evaluate offers and are listed in descending order of importance. 1) Technical Understanding and Approach. The proposed technology will be evaluated on its ability to be successfully implemented into FDA’s standard environment and the use of the technology. Contractors shall furnish as part of their quotation all descriptive material necessary for the government to determine whether their service meets the technical requirements. The technical proposals will be graded subjectively with final scores of, “Acceptable” or “Unacceptable”. A score of “Acceptable” would mean that the proposed technology fully met the requirements and demonstrated its ability to be implemented. A score of “Unacceptable” would mean that the proposed technology failed to meet the minimum requirements. 2) Price. Price is of less importance than technical capabilities and past performance combined. Award will not be automatically made on the basis of the highest technical merit. However price may become an important factor as the degree of equality between technical proposals becomes closer. 3) Past performance -Offeror should provide three references of similar efforts performed during the last three years. This will include a description of the project, project title, contract number, contract amount, client identification including agency or company name, contracting and technical reviewing official name(s), address and telephone number. Rating of positive, neutral, and poor will be given. A positive past performance will take precedence over neutral or poor past performance. Neutral past performance takes precedence over poor past performance. A contractor with no past performance will be given a score of neutral, which will neither be used to the advantage nor disadvantage of the offeror. The Government intends to issue one firm fixed award for this requirement. The Government reserves the right to make award without discussions. (ix) Vendors shall complete FAR 52.212-3, Offerors Representations and Certifications - Commercial Items (JUN 2003). This can be done electronically at http://orca.bpn.gov. The contracting officer will review the vendor’s online certifications at http://orca.bpn.gov to ensure that they are accurate and complete. If the vendor does not have active representations and certifications registered online they will be disqualified from being considered for award. (xii) The clause at 52.212-4, Contract Terms and Conditions - Commercial Items (FEB 2007), applies to this acquisition. (xiii) The clause at FAR 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders - Commercial Items (JUNE 2007), applies to this acquisition as well as the following clauses cited therein: 52.219-6, Notice of Total Small Business Set-Aside (JUN 2003) (Alternate I OCT 1995), 52.222-3, Convict Labor (JUN 2003)(EO 11755); 52.222-19, Child Labor - Cooperation with Authorities and Remedies (JAN 2006)(EO13126); 52.222-21, Prohibition of Segregated Facilities (FEB 1999); 52.222-26, Equal Opportunity (MAR 2007)(EO11246); 52.222-35, Equal Opportunity for Special Disabled Veterans, Veterans of the Vietnam Era and other Eligible Veterans (SEP 2006)(38 USC 4212); 52.222-36, Affirmative Action for Workers with Disabilities (JUN 1998)(29 USC 793); 52.222-37, Employment Reports on Special Disabled Veterans, Veterans of the Vietnam Era and other Eligible Veterans; 52.232-34 (SEP 2006)(38 USC 4212) Payment by Electronic Funds Transfer - Other than Central Contractor Registration (MAY 1999), 52.225-1 Buy American Act---Supplies (JUN 2003), 52.225-13 Restriction on Certain Foreign Purchases (FEB 2006), 52.239-1 Privacy or Security Safeguards (AUG 1996) (5 U.S.C. 552a). Full text of clauses and provisions can be accessed at www.arnet.gov/far. (xiv) In order to comply with Section 508 of the Rehabilitation Act, the Government asks vendors to complete a Voluntary Product Accessibility Template (VPAT) and submit it with their quote. The technical standards applicable to this requirement are: 1194.21 Software Applications and Operating Systems (a,b,c,d,e,f,g,h,i,j,l), 1194.22 Web-based Intranet and Internet Information and Applications, and 1194.41 Information, Documentation, and Support (a,b,c).. The 508 technical standards are available at http://www.section508.gov/. All questions must be submitted in writing to Rafael.taylor@fda.hhs.gov or Jody.O’Kash@fda.hhs.gov no later than Tuesday, September 9, 2008 at 5pm EST. Answers to all questions will be posted as an amendment to the solicitation. Proposals, Technical proposals, and VPAT may be submitted electronically at Rafael.taylor@fda.hhs.gov and/or Jody.O'Kash@fda.hhs.gov no later than Wednesday, September 11, 2008 at 1pm EST.
- Web Link
-
FedBizOpps Complete View
(https://www.fbo.gov/?s=opportunity&mode=form&id=9eba796bc6f34dd838b7e258c1a5df50&tab=core&_cview=1)
- Place of Performance
- Address: Office of Clinical Pharmacology, Office of Translational Science, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, 10903 New Hampshire Avenue, Building 51, Room 2148, Silver Spring, MD 20903-0002, Silver Spring, Maryland, 20903-0002, United States
- Zip Code: 20903-0002
- Zip Code: 20903-0002
- Record
- SN01662474-W 20080910/080908220023-9eba796bc6f34dd838b7e258c1a5df50 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |